The other point you raised on orphan drugs, which I thought was really interesting, was that a national program could operate as a mechanism for raising the quality of care, because caregivers and treatment centres for those conditions, which know how to effectively manage them, are usually scarce, so if you tie the pharma component to those, you could get a great outcome. Are you aware of the jurisdictions that have done that? I get the theory of it.
On May 30th, 2016. See this statement in context.